Vor Biopharma Inc.

NasdaqGS:VOR Rapport sur les actions

Capitalisation boursière : US$54.3m

Vor Biopharma Bilan de santé

Santé financière contrôle des critères 4/6

Vor Biopharma possède un total de capitaux propres de $73.0M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $116.0M et de $43.0M.

Informations clés

0%

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$62.81m
Fonds propresUS$72.96m
Total du passifUS$43.04m
Total des actifsUS$115.99m

Mises à jour récentes de la santé financière

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Sep 10
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Dec 05
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Aug 18
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Recent updates

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Sep 10
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Dec 05
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Aug 18
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

May 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Mar 13
Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Oct 19
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Bio appoints Eyal C. Attar as chief medical officer

Oct 12

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Jun 18
Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Mar 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Aug 30
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma: Targeted Therapies For Transplants

Jun 30

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 10
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma EPS misses by $0.03

May 06

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de VOR ( $67.3M ) dépassent ses passifs à court terme ( $14.3M ).

Passif à long terme: Les actifs à court terme de VOR ( $67.3M ) dépassent ses passifs à long terme ( $28.7M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: VOR est sans dette.

Réduire la dette: VOR n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 28%.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: VOR dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: VOR dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 29.6 % chaque année


Découvrir des entreprises saines